Hypothesis

Rapamycin extends lifespan by mimicking famine‑induced conservation programs, but its hormetic effect is limited when senescent‑cell‑derived SASP maintains a pro‑inflammatory milieu that antagonizes FOXO and NRF2 activation. Prior removal of senescent cells with a senolytic will therefore potentiate rapamycin‑driven lifespan and healthspan gains.

Mechanistic rationale

• Rapamycin inhibits mTORC1/2, shifting resources from growth to autophagy and stress resistance [1] [2].
• Senescent cells secrete IL‑6, IL‑1β and TGF‑β, which activate NF‑κB and STAT3 pathways that suppress FOXO transcriptional activity and blunt NRF2‑mediated antioxidant responses.
• Clearing senescent cells lowers circulating SASP factors, raising NAD+/NADH ratios and activating SIRT1, which deacetylates and stabilizes FOXO proteins and promotes NRF2 nuclear translocation.
• With SASP suppressed, rapamycin‑induced autophagy and reduced protein synthesis can more effectively engage FOXO/NRF2 target genes (e.g., SOD2, CAT, GCLC) without competing inhibitory signals.

Predictions

1. Mice receiving a senolytic (e.g., dasatinib + quercetin) followed by intermittent rapamycin will show a greater increase in median and maximum lifespan than either treatment alone.
2. The combination will produce lower plasma SASP biomarkers (IL‑6, TNF‑α) and higher hepatic FOXO1/NRF2 target expression than rapamycin monotherapy.
3. Healthspan metrics (grip strength, glucose tolerance, frailty index) will improve more markedly in the sequential group.
4. If senolytic pretreatment does not augment rapamycin’s lifespan effect, the hypothesis is falsified.

Experimental design

• Animals: 20‑month‑old C57BL/6J mice (n=15 per group).
• Groups: (1) Vehicle control, (2) Senolytic alone (dasatinib 5 mg/kg + quercetin 50 mg/kg, oral, weekly ×3), (3) Rapamycin alone (14 ppm in diet, intermittent 5 days on/2 days off), (4) Senolytic → rapamycin (senolytic regimen as above, followed 2 weeks later by rapamycin schedule).
• Measurements: Survival monitored until natural death; blood collected at 3, 6, 9 months post‑start for SASP cytokines (ELISA); liver harvested at endpoint for FOXO1, NRF2, LC3‑II, p‑S6K Western blots; functional assays (rotarod, grip strength, GTT) every 2 months.

Potential outcomes

• Supportive: Group 4 exhibits ~15 % longer median lifespan vs. group 3, alongside reduced SASP and elevated FOXO/NRF2 activity, confirming that damage clearance primes hormetic pathways.
• Refuting: No significant lifespan difference between groups 3 and 4, or SASP levels unchanged despite senolytic treatment, indicating that rapamycin’s effect is independent of senescent‑cell burden.

Implications

If validated, this model would reposition rapamycin not merely as a "hard‑life impersonator" but as a stress‑response amplifier whose efficacy is gated by the inflammatory landscape. It would suggest that combinatorial gerotherapeutics targeting damage clearance before mTOR inhibition could achieve greater longevity benefits than either approach alone, informing clinical trial design for aging‑related therapeutics.